Validation of a post-transplant chronic lung allograft dysfunction classification system
- PMID: 30391199
- DOI: 10.1016/j.healun.2018.09.020
Validation of a post-transplant chronic lung allograft dysfunction classification system
Abstract
Background: Long-term survival after lung transplantation (LTx) is hampered by chronic lung allograft dysfunction (CLAD). Our study evaluated the prevalence and prognostic importance of obstructive and restrictive CLAD phenotypes, with or without an identifiable underlying cause, to validate the recently proposed classification system for CLAD.
Methods: Data for patients who underwent LTx between 2004 and 2015 with a minimal survival of 180 days post-LTx were retrospectively collected. Double LTx patients with CLAD (defined as a persistent forced expiratory volume in 1 second decline of ≥ 20% compared with baseline) were subsequently classified according to obstructive (forced expiratory volume in 1 second /forced vital capacity [FVC] < 70%, total lung capacity > 90%, and FVC > 80%) or restrictive (total lung capacity ≤ 90% or FVC ≤ 80%) pulmonary function and to the presence of an unknown (bronchiolitis obliterans syndrome [BOS]/restrictive allograft syndrome [RAS]) or known (non-BOS/non-RAS) underlying cause.
Results: After a median of 3.2 years, CLAD developed in 39% of double LTx patients (n = 219), of which 20% (n = 43) had an identifiable cause. Survival was worse in patients with restrictive CLAD (26%) compared with obstructive CLAD (64%; p < 0.0001). Non-BOS patients suffered from inferior survival compared with BOS patients (p = 0.0016), whereas there was no significant difference in survival between RAS and non-RAS (p = 0.17). Patients who evolved from an obstructive (BOS) to a restrictive (RAS) phenotype (10%) experienced better survival than RAS patients and a worse outcome compared with BOS patients (p < 0.0001).
Conclusions: Given the differences in outcome, accurate diagnosis of CLAD phenotypes is important, because this helps to inform patients about their prognosis, to reveal underlying pathogenesis, to identify homogenous patient populations for clinical trials, and to guide future therapeutic approaches.
Keywords: chronic lung allograft dysfunction; lung transplantation; outcome; phenotype; survival.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.J Heart Lung Transplant. 2011 Jul;30(7):735-42. doi: 10.1016/j.healun.2011.01.712. Epub 2011 Mar 17. J Heart Lung Transplant. 2011. PMID: 21419659
-
Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction.J Heart Lung Transplant. 2019 Feb;38(2):184-193. doi: 10.1016/j.healun.2018.10.006. Epub 2018 Oct 31. J Heart Lung Transplant. 2019. PMID: 30466803 Free PMC article.
-
Low-dose computed tomography volumetry for subtyping chronic lung allograft dysfunction.J Heart Lung Transplant. 2016 Jan;35(1):59-66. doi: 10.1016/j.healun.2015.07.005. Epub 2015 Aug 13. J Heart Lung Transplant. 2016. PMID: 26342441
-
Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS).Semin Respir Crit Care Med. 2013 Jun;34(3):352-60. doi: 10.1055/s-0033-1348463. Epub 2013 Jul 2. Semin Respir Crit Care Med. 2013. PMID: 23821509 Review.
-
Chronic Lung Allograft Dysfunction.Thorac Surg Clin. 2022 May;32(2):231-242. doi: 10.1016/j.thorsurg.2021.11.004. Thorac Surg Clin. 2022. PMID: 35512941 Review.
Cited by
-
Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms.Transplantation. 2025 Mar 1;109(3):454-466. doi: 10.1097/TP.0000000000005162. Epub 2024 Aug 6. Transplantation. 2025. PMID: 39104003 Review.
-
Time to Rethink Bronchiolitis Obliterans Syndrome Following Lung or Hematopoietic Cell Transplantation in Pediatric Patients.Cancers (Basel). 2024 Nov 4;16(21):3715. doi: 10.3390/cancers16213715. Cancers (Basel). 2024. PMID: 39518153 Free PMC article. Review.
-
Transition from BOS to RAS impairs prognosis after lung transplantation-CLAD subtype analysis by CT volumetry.PLoS One. 2022 Oct 12;17(10):e0275563. doi: 10.1371/journal.pone.0275563. eCollection 2022. PLoS One. 2022. PMID: 36223371 Free PMC article.
-
Blood MMP-9 measured at 2 years after lung transplantation as a prognostic biomarker of chronic lung allograft dysfunction.Respir Res. 2024 Feb 9;25(1):88. doi: 10.1186/s12931-024-02707-3. Respir Res. 2024. PMID: 38336710 Free PMC article.
-
Graft dysfunction and rejection of lung transplant, a review on diagnosis and management.Clin Respir J. 2022 Jan;16(1):5-12. doi: 10.1111/crj.13471. Epub 2022 Jan 25. Clin Respir J. 2022. PMID: 35080130 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical